cisplatin + toripalimab + vinorelbine

This is a combination regimen consisting of three drugs: - **Cisplatin** is a platinum-based chemotherapy agent that forms DNA crosslinks, leading to apoptosis in rapidly dividing cells. - **Toripalimab** is a monoclonal antibody targeting the programmed cell death protein 1 (PD-1) receptor, functioning as an immune checkpoint inhibitor to enhance anti-tumor immune responses. - **Vinorelbine** is a vinca alkaloid chemotherapy that inhibits microtubule assembly, thereby blocking mitosis and cell division in cancer cells[1][2][6]. This combination may be used investigationally or off-label for certain cancers such as non-small cell lung cancer (NSCLC), leveraging both cytotoxic and immunotherapeutic mechanisms.